StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) stock

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.99+0.19 (+1.13%)

Close on Nov 18, 2026Market cap $3.10BP/E –Yield –

Xeris Biopharma pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Xeris Biopharma's pe ratio was 161.6× on Jul 31, 2026.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Jul 31, 2026161.6×–

More Xeris Biopharma figures

See a number that looks wrong?